John Kao's recent insider purchase indicates confidence in the company's future, despite longer-term transactions showing more selling than buying. However, the level of insider ownership suggests a reasonable alignment between insiders and shareholders.
Despite Alignment Healthcare's strong revenue growth and positive future outlook, its P/S ratio is average, indicating investor skepticism. The falling share price and market's doubt in its growth may signal potential risks.
Despite being unprofitable last year, the company's strong revenue growth could lead to profitability. However, it's riskier due to a loss of US$158m and burning through US$53m of cash.
Gapping up In reaction to earnings/guidance: •$オートゾーン(AZO.US)$+2.7%,$ジェイコブズ・ソリューション(J.US)$+0.9% (reaffirms Q4 EPS and adjusted EBITDA guidance) Other news: •$パープル・イノベーション(PRPL.US)$+32.6% (confirms it received an unsolicited, non-binding proposal from Coliseum Capital Management to acquire all of the outstanding capital stock of Purple for $4.35 per share) •$KnowBe4(KNBE.US)$+24.9% (received a non-binding proposal f...
Gapping up In reaction to earnings/guidance: •$ボウレロ・コーポレーション(BOWL.US)$+3.4% Other news: •$インテリア・セラピューティクス(NTLA.US)$+10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002) •$ゴーゴー(GOGO.US)$+5% (Repurchases 1.5 million shares of common stock from BlackRock) •$ADCセラピューティクス(ADCT.US)$+2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
BOFA •$オスカー・ヘルス(OSCR.US)$BofA analyst Kevin Fischbeck downgraded Oscar Health to Neutral from Buy with a price target of $6, down from $12. The analyst sees greater medical loss ratio uncertainty into 2023. The industry is going to have to manage through the expiration of the expanded Affordable Care Act subsidies, Medicaid redeterminations and the result shift within the risk pool making it more difficult to price, Fischb...
アラインメント・ヘルスケアに関するコメント
Still loading zone for long term investors here
Love stakeholder long term hold potential as the float is high
コラムToday's Pre-Market Stock Movers: TTWO, AZO, BLUE, PRPL and More
In reaction to earnings/guidance:
• $オートゾーン(AZO.US)$ +2.7%,$ジェイコブズ・ソリューション(J.US)$ +0.9% (reaffirms Q4 EPS and adjusted EBITDA guidance)
Other news:
• $パープル・イノベーション(PRPL.US)$ +32.6% (confirms it received an unsolicited, non-binding proposal from Coliseum Capital Management to acquire all of the outstanding capital stock of Purple for $4.35 per share)
• $KnowBe4(KNBE.US)$ +24.9% (received a non-binding proposal f...
コラムToday's Pre-Market Stock Movers: FDX, UBER, GE, NTLA and More
In reaction to earnings/guidance:
• $ボウレロ・コーポレーション(BOWL.US)$ +3.4%
Other news:
• $インテリア・セラピューティクス(NTLA.US)$ +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
• $ゴーゴー(GOGO.US)$ +5% (Repurchases 1.5 million shares of common stock from BlackRock)
• $ADCセラピューティクス(ADCT.US)$ +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
コラムAnalysts' screen via BofA, JPMorgan, Morgan Stanley, Mizuho and more
• $オスカー・ヘルス(OSCR.US)$ BofA analyst Kevin Fischbeck downgraded Oscar Health to Neutral from Buy with a price target of $6, down from $12. The analyst sees greater medical loss ratio uncertainty into 2023. The industry is going to have to manage through the expiration of the expanded Affordable Care Act subsidies, Medicaid redeterminations and the result shift within the risk pool making it more difficult to price, Fischb...
まだコメントはありません